Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-a8d190f59e73033fd1157419aef18ccc"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-a8d190f59e73033fd1157419aef18ccc"/>
<resource>
<Composition>
<id value="composition-en-a8d190f59e73033fd1157419aef18ccc"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-a8d190f59e73033fd1157419aef18ccc"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-a8d190f59e73033fd1157419aef18ccc</b></p><a name="composition-en-a8d190f59e73033fd1157419aef18ccc"> </a><a name="hccomposition-en-a8d190f59e73033fd1157419aef18ccc"> </a><a name="composition-en-a8d190f59e73033fd1157419aef18ccc-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/09/522/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ellaone</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/09/522/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpa8d190f59e73033fd1157419aef18ccc"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - ellaone"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><ul><li>Useful information about contraception</li></ul></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What ellaOne is and what it is used for</li><li>What you need to know before you take ellaOne</li><li>How to take ellaOne</li><li>Possible side effects</li><li>How to store ellaOne</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What ellaone is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What ellaone is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>ellaOne is an emergency contraceptive</p><p>ellaOne is a contraceptive intended to prevent pregnancy after unprotected sex or if your contraceptive method has failed. For example:</p><p>if you had sex without protection;</p><p>if your or your partner s condom tore, slipped or came off, or if you forgot to use one;</p><p>if you did not take your contraceptive pill as recommended.</p><p>You should take the tablet as soon as possible after sex, and within a maximum of 5 days (120 hours). This is because it is more effective if you take it as soon as possible after unprotected sex.</p><p>This medicine is suitable for any woman of childbearing age, including adolescents.</p><p>You can take the tablet at any time in the menstrual cycle.</p><p>ellaOne does not work if you are already pregnant</p><p>If your menstrual period is late, there is a possibility that you may be pregnant. When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet.</p><p>If you have unprotected sex after taking the tablet, it will not stop you from becoming pregnant. Unprotected sex at any time during your cycle can lead to pregnancy.</p><p>ellaOne is not to be used for regular contraception</p><p>If you do not have a regular method of contraception, talk to your doctor or healthcare professional to choose one that is suitable for you.</p><p>How ellaOne works</p><p>ellaOne contains the substance ulipristal acetate which acts by modifying the activity of the natural hormone progesterone which is necessary for ovulation to occur. As a result, this medicine works by postponing ovulation. Emergency contraception is not effective in every case. Of 100 women who take this medicine approximately 2 will become pregnant.</p><p>This medicine is a contraceptive used to prevent a pregnancy from starting. If you are already pregnant, it will not interrupt an existing pregnancy.</p><p>Emergency contraception does not protect against sexually transmitted infections</p><p>Only condoms can protect you from sexually transmitted infections. This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis). Ask a healthcare professional for advice if you are worried about this.</p><p>There is more information about contraception at the end of this leaflet.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take ellaone"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take ellaone"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take ellaOne</p><p>if you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6).</p><p>Warning and precautions Talk to your pharmacist, doctor or other healthcare professional before taking this medicine</p><p>if your period is late or you have symptoms of pregnancy (heavy breasts, morning sickness), as you may already be pregnant (see section Pregnancy, breast-feeding and fertility );</p><p>if you suffer from severe asthma;</p><p>if you suffer from severe liver disease.</p><p>In all women, emergency contraception should be taken as soon as possible after unprotected intercourse. There is some evidence that this medicine may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive. Therefore, ellaOne is still recommended for all women regardless of their weight or BMI.</p><p>You are advised to speak to a healthcare professional if you are concerned about any problems related to taking emergency contraception.</p><p>If you become pregnant despite taking the tablet, it is important that you see your doctor. See section Pregnancy, breast-feeding and fertility for more information.</p><p>Other contraceptives and ellaOne This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective. If you are currently taking hormonal contraception, continue to use it as usual after taking this medicine, but be sure to use condoms every time you have sex until your next period.</p><p>Do not take this medicine together with another emergency contraceptive pill that contains levonorgestrel. By taking them both together, you might make this medicine less effective.</p><p>Other medicines and ellaOne Tell your pharmacist, doctor or other healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or herbal medicines.</p><p>Some medicines may prevent ellaOne from working effectively. If you have used any of the medicines listed below during the last 4 weeks, ellaOne may be less suitable for you. Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD):</p><p>medicines used to treat epilepsy (for example, primidone, phenobarbital, phenytoin, fosphenytoine, carbamazepine, oxcarbazepine and barbiturates)</p><p>medicines used to treat tuberculosis (for example, rifampicin, rifabutin)</p><p>a treatment for HIV (ritonavir, efavirenz, nevirapine)</p><p>a medicine used to treat fungal infections (griseofulvin)</p><p>herbal remedies containing St John's wort (Hypericum perforatum).</p><p>Speak to your doctor or pharmacist before using ellaOne when you use (or have recently used) any of the medicines stated above.</p><p>Pregnancy, breast-feeding and fertility<br/>Pregnancy</p><p>Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section Warning and precautions ).</p><p>This medicine is a contraceptive used to prevent a pregnancy from starting. If you are already pregnant it will not interrupt an existing pregnancy.</p><p>If you become pregnant despite taking this medicine, there is no evidence that it will affect your pregnancy. However, it is important that you see your doctor. As for any pregnancy, your doctor may want to check that the pregnancy is not outside the womb. This is especially important if you have severe abdominal (stomach) pain or bleeding or if you have previously had a pregnancy outside the womb, tubal surgery or long term (chronic) genital infection.</p><p>If you become pregnant despite taking ellaOne, you are encouraged to ask your doctor to register your pregnancy in an official registry. You can also report this information on your own at <a href="http://www.hra-pregnancy-registry.com.Your">www.hra-pregnancy-registry.com.Your</a> information will remain anonymous nobody will know it is information about you. Sharing your information may help women in the future understand the safety or risks of ellaOne during a pregnancy.</p><p>Breast-feeding</p><p>If you take this medicine while you are breast-feeding a baby, do not breast-feed for one week after taking this medicine. During this time, it is recommended to use a breast pump in order to maintain milk production, but throw away your breast milk. The effect of breast-feeding your baby in the week after taking this medicine is not known.</p><p>Fertility</p><p>This medicine will not affect your future fertility. If you have unprotected sex after taking the tablet, it will not stop you from becoming pregnant. Therefore it is important you use condoms until your next period.<br/>If you wish to start or continue with a regular method of contraception after using this medicine, you can do so but you should also use condoms until your next period.</p><p>Driving and using machines After taking this medicine, some women experience dizziness, drowsiness, blurred vision and/or loss of concentration (see section 4). If you experience these symptoms, do not drive or use machines</p><p>ellaOne contains lactose<br/>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>ellaOne contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take ellaone"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take ellaone"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as described in this leaflet or as your pharmacist, doctor or other healthcare professional has told you. Check with your pharmacist or doctor if you are not sure.</p><p>How to take the ellaOne tablet</p><p>Take one tablet by mouth as soon as possible and no later than 5 days (120 hours) after unprotected sex or contraceptive failure. Take the tablet without delay.</p><p>You can take the tablet at any time in your cycle.</p><p>You can take the tablet at any time of the day either before, during or after a meal.</p><p>If you are using one of the medicines that may prevent ellaOne from working properly (see section 2 What you need to know before you take ellaOne ) or if you have used one of these medicines in the past 4 weeks, ellaOne may work less effectively for you. Speak to your doctor or pharmacist before using ellaOne. Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a Cu-IUD.</p><p>If you vomit after taking ellaOne</p><p>If you vomit (be sick, throw up) within 3 hours of taking the tablet, take another tablet as soon as possible.</p><p>If you have sex again after taking ellaOne</p><p>If you have unprotected sex after taking the tablet, it will not stop you from becoming pregnant. After you take the tablet and until your next period comes, you should use condoms every time you have sex.</p><p>If your next period is late after taking ellaOne</p><p>After taking the tablet, it is normal for your next period to be a few days late. However, if your period is more than 7 days late; if it is unusually light or unusually heavy; or if you experience symptoms such as abdominal (stomach) pain, breast tenderness, vomiting or nausea, you may be pregnant. You should do a pregnancy test right away. If you are pregnant, it is important that you see your doctor. (See section Pregnancy, breast-feeding and fertility )</p><p>If you take more ellaOne than you should</p><p>There have been no reports of harmful effects from taking a higher dose than recommended of this medicine However do ask your pharmacist, doctor or other healthcare professional for advice. If you have any further questions on the use of this medicine, ask your pharmacist, doctor or other healthcare professional.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some symptoms such as breast tenderness and abdominal (stomach) pain, throwing up (vomiting), feeling sick (nausea) are also possible signs of pregnancy. If you miss your period and experience such symptoms after taking ellaOne, you should do a pregnancy test (see section 2 Pregnancy, breast- feeding and fertility ).</p><p>Common side effects (may affect up to 1 in 10 people)</p><p>nausea, abdominal (stomach) pain or discomfort, vomiting</p><p>painful periods, pelvic pain, breast tenderness</p><p>headache, dizziness, mood swings</p><p>muscle pain, back pain, tiredness</p><p>Uncommon side effects (may affect up to 1 in 100 people)</p><p>diarrhoea, heartburn, wind, dry mouth</p><p>unusual or irregular vaginal bleeding, heavy/prolonged periods premenstrual syndrome, vaginal irritation or discharge, lesser or greater sex drive</p><p>hot flushes</p><p>appetite changes, emotional disorders, anxiety, agitation, trouble sleeping, sleepiness, migraine visual disturbances</p><p>influenza</p><p>acne, skin lesions, itching</p><p>fever, chills, malaise</p><p>Rare side effects (may affect up to 1 in 1,000 people)</p><p>genital pain or itching, pain during sex, rupture of an ovarian cyst, unusually light period</p><p>loss of concentration, vertigo, shaking, disorientation, fainting</p><p>unusual sensation in eye, red eye, sensitivity to light</p><p>dry throat, disturbance in taste</p><p>allergic reactions such as rash, hives or swelling of the face</p><p>feeling thirsty</p><p>Reporting of side effects If you get any side effects, talk to your pharmacist, doctor or other healthcare professional. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store ellaone"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store ellaone"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is on the carton and on the blister after EXP. The expiry date refers to the last day of that month.</p><p>Store below 25 C. Store in the original package in order to protect from moisture. Keep the blister in the outer carton in order to protect from light.</p><p>Do not throw away any medicines via waste water. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What ellaOne contains</p><p>The active substance is ulipristal acetate. Each tablet contains 30 milligrams of ulipristal acetate.</p><p>The other ingredients are lactose monohydrate, povidone, croscarmellose sodium, magnesium stearate.</p><p>What ellaOne looks like and contents of the pack ellaOne is a white to marble creamy, round curved tablet of 9 mm diameter engraved with ll on both sides.</p><p>ellaOne is available in a carton containing one blister of 1 tablet.</p><p>Marketing Authorisation Holder<br/>LABORATOIRE HRA PHARMA 200 avenue de Paris 92320 CHATILLON France E-mail: <a href="mailto:info-ella@hra-pharma.com">info-ella@hra-pharma.com</a></p><p>Manufacturer Cenexi 17, rue de Pontoise 95520 Osny France</p><p>Laboratorios Le n Farma S.A. C/ La Vallina, s/n Pol. Ind. Navatejera 24008 Navatejera, Le n Spain</p><p>Delpharm Lille S.A.S. Parc d activit s Roubaix-Est 22, rue de Toufflers CS 5059452 Lys-Lez-Lannoy France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder</p><p>Belgi /Belgique/Belgien Perrigo Belgium NV +32 (0)9 381 04 Lietuva Orivas UAB Tel: +370 5 252 6<br/>Perrigo Bulgaria OOD Tel: +359 2805 7Luxembourg/Luxemburg Perrigo Belgium NV +32 (0)9 381 04 esk republika Omega Pharma a.s. Tel : +420 603 407 Magyarorsz g Zentiva Pharma Kft. Tel.: + 36 1 299 1Danmark Perrigo Sverige AB Tel: +46 8 59 00 29 Malta Laboratoire HRA Pharma Tel: + 33-(0)1 40 33 11 Deutschland Perrigo Deutschland GmbH +49 7032 9154 Nederland Omega Pharma Nederland BV Tel: +31 (0) 10 2211Eesti Orivas O<br/>Tel: +372 639 8Norge Perrigo Sverige AB Tel: +46 8 59 00 29<br/>. . : + 30 210 8009111- sterreich Perrigo Deutschland GmbH +49 7032 9154 Espa a Perrigo Espa a, S.A. Polska Perrigo Poland Sp. z o.o.</p><p>Tel: +34 902 889 Tel: +48 (22) 489 54 France Laboratoire Perrigo France T l/Tel: + 33-(0) 1 55 48 18 Portugal Perrigo Portugal Lda. Tel: +351 214 167 Hrvatska Arenda d.o.o. Tel: + 385-(0)1 644 44 Rom nia Perrigo Romania S.R.L.<br/>Tel: +40 213 150 Ireland Laboratoire HRA Pharma Tel: + 33-(0)1 40 33 11 Slovenija Dr. Gorki d.o.o. Tel: + 386-(0)1 7590 sland Laboratoire HRA Pharma S mi: + 33-(0)1 40 33 11 Slovensk republika Omega Pharma a.s. Tel : +420 603 407 Italia Perrigo Italia S.r.l Tel: + 39 06 90250Suomi/Finland Perrigo Sverige AB Tel: +46 8 59 00 29<br/>. . : + 30 210 8009111-Sverige Perrigo Sverige AB Tel: +46 8 59 00 29 Latvija Orivas SIA Tel: +371 676 124 United Kingdom (Northern Ireland) Laboratoire HRA Pharma Tel: + 33-(0)1 40 33 11 This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpa8d190f59e73033fd1157419aef18ccc"/>
<resource>
<MedicinalProductDefinition>
<id value="mpa8d190f59e73033fd1157419aef18ccc"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpa8d190f59e73033fd1157419aef18ccc"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpa8d190f59e73033fd1157419aef18ccc</b></p><a name="mpa8d190f59e73033fd1157419aef18ccc"> </a><a name="hcmpa8d190f59e73033fd1157419aef18ccc"> </a><a name="mpa8d190f59e73033fd1157419aef18ccc-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/09/522/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: ellaOne 30 mg tablet</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/09/522/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="ellaOne 30 mg tablet"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
